Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript
03:56am, Wednesday, 08'th May 2024
Certara, Inc. (NASDAQ:CERT ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher -
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
07:41pm, Tuesday, 07'th May 2024
Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago.
Certara Reports First Quarter 2024 Financial Results
04:15pm, Tuesday, 07'th May 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
08:00am, Tuesday, 16'th Apr 2024
Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
04:15pm, Tuesday, 09'th Apr 2024
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
09:33pm, Thursday, 29'th Feb 2024
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
07:06pm, Thursday, 29'th Feb 2024
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
Certara Reports Fourth Quarter 2023 Financial Results
04:10pm, Thursday, 29'th Feb 2024
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and ful
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
11:44am, Tuesday, 30'th Jan 2024
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and devel
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
04:30pm, Tuesday, 21'st Nov 2023
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Inc. (CERT) Q3 2023 Earnings Call Transcript
10:41pm, Wednesday, 08'th Nov 2023
Certara Inc. (NASDAQ:CERT ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagh
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
08:17pm, Wednesday, 08'th Nov 2023
Certara, Inc. (CERT) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.10 per share a year ago.
Certara Reports Third Quarter 2023 Financial Results
04:10pm, Wednesday, 08'th Nov 2023
PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023.
